Impact of HIF prolyl hydroxylase inhibitors in heart failure patients with renal anemia

被引：0
|
作者：
Takahiro Kambara
Rei Shibata
Yuusuke Sakamoto
Teruhiro Sakaguchi
Hiroyuki Osanai
Yoshihito Nakashima
Hiroshi Asano
Toyoaki Murohara
Masayoshi Ajioka
机构：
[1] Tosei General Hospital,Department of Cardiovascular Medicine
[2] Nagoya University Graduate School of Medicine,Department of Advanced Cardiovascular Therapeutics
[3] Nagoya University Graduate School of Medicine,Department of Cardiology
来源：
BMC Research Notes | / 17卷
关键词：
Heart failure; HIF-PH inhibitor; NT-proBNP; Renal anemia; Ferritin; TSAT;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Inhibition of HIF prolyl-hydroxylase domain to correct anemia in patients with chronic kidney disease
    Wyatt, Christina M.
    Drueke, Tilman B.
    KIDNEY INTERNATIONAL, 2020, 97 (04) : 639 - 642
  • [22] Endogenous 2-oxoglutarate levels impact potencies of competitive HIF prolyl hydroxylase inhibitors
    Thirstrup, Kenneth
    Christensen, Soren
    Moller, Henriette Aaris
    Ritzen, Andreas
    Bergstrom, Ann-Louise
    Sager, Thomas Nikolaj
    Jensen, Henrik Sindal
    PHARMACOLOGICAL RESEARCH, 2011, 64 (03) : 268 - 273
  • [23] Updates on hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of renal anemia
    Li, Jing
    Haase, Volker H. H.
    Hao, Chuan-Ming
    KIDNEY DISEASES, 2023, 9 (01) : 1 - 11
  • [24] Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Patients with Renal Anemia: A Meta-Analysis of Randomized Trials
    Wen, Tong
    Zhang, Xinzhou
    Wang, Zhen
    Zhou, Ru
    NEPHRON, 2020, 144 (11) : 572 - 582
  • [25] Prolyl hydroxylase inhibitors for the treatment of anemia in chronic kidney disease
    Cases, A.
    Vera, M.
    Ojeda, R.
    Gorriz, J. L.
    DRUGS OF THE FUTURE, 2018, 43 (01) : 23 - 33
  • [26] ExActa HIF prolyl hydroxylase inhibitors-The new lifestyle drug?
    Sciesielski, Lina K.
    Kirschner, Karin M.
    ACTA PHYSIOLOGICA, 2019, 227 (03)
  • [27] Molecular and cellular mechanisms of HIF prolyl hydroxylase inhibitors in clinical trials
    Yeh, Tzu-Lan
    Leissing, Thomas M.
    Abboud, Martine I.
    Thinnes, Cyrille C.
    Atasoylu, Onur
    Holt-Martyn, James P.
    Zhang, Dong
    Tumber, Anthony
    Lippl, Kerstin
    Lohans, Christopher T.
    Leung, Ivanhoe K. H.
    Morcrette, Helen
    Clifton, Ian J.
    Claridge, Timothy D. W.
    Kawamura, Akane
    Flashman, Emily
    Lu, Xin
    Ratcliffe, Peter J.
    Chowdhury, Rasheduzzaman
    Pugh, Christopher W.
    Schofield, Christopher J.
    CHEMICAL SCIENCE, 2017, 8 (11) : 7651 - 7668
  • [28] HIF-α Prolyl Hydroxylase Inhibitors and Their Implications for Biomedicine: A Comprehensive Review
    Hirota, Kiichi
    BIOMEDICINES, 2021, 9 (05)
  • [29] HIF-Prolyl Hydroxylase Inhibitors: Confirmed Efficacy with Uncertain Safety
    Roger, Simon D.
    Coyne, Daniel W.
    AMERICAN JOURNAL OF NEPHROLOGY, 2021, 52 (10-11) : 894 - 897
  • [30] IMPACT OF EMERGING HIF-PH INHIBITORS ON RENAL ANEMIA TREATMENT
    Khan, J.
    Blackstock, T.
    Privolnev, Y.
    Moore, R.
    VALUE IN HEALTH, 2018, 21 : S479 - S479
12345